UroGen Pharma (URGN) CFO awarded 32,609 restricted stock units vesting through 2029

Rhea-AI Filing Summary

UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.

According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Degnan Chris

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		A		32,609		(2)	(2)	Ordinary Shares	32,609	$0	32,609	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

2. 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.

	/s/ Jason D. Smith, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UroGen Pharma (URGN) report for its CFO?

UroGen Pharma reported that Chief Financial Officer Chris Degnan received a grant of 32,609 restricted stock units on January 31, 2026. Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma, aligning his compensation with future company performance.

How many restricted stock units were granted to the UroGen Pharma (URGN) CFO?

The CFO of UroGen Pharma, Chris Degnan, was granted 32,609 restricted stock units. These RSUs are derivative securities that convert into ordinary shares upon vesting, giving him a potential future ownership stake matching 32,609 ordinary shares if all vesting conditions are satisfied.

When do the UroGen Pharma (URGN) CFO’s RSUs vest?

The RSUs granted to UroGen Pharma’s CFO vest in three equal installments. One-third of the underlying shares vests on January 31, 2027, another third on January 31, 2028, and the final third on January 31, 2029, subject to applicable vesting conditions.

What does each UroGen Pharma (URGN) RSU granted to the CFO represent?

Each restricted stock unit granted to the CFO represents a contingent right to receive one ordinary share of UroGen Pharma. This means no share is issued immediately; shares are delivered only when RSUs vest, assuming the vesting requirements continue to be met over time.

What is the ownership form of the UroGen Pharma (URGN) CFO’s RSUs after this grant?

After the January 31, 2026 grant, the CFO directly holds 32,609 derivative securities in the form of RSUs. The filing indicates a direct ownership form, meaning these units are attributed personally to him rather than to a separate trust, partnership, or related entity.

Was there a purchase price for the UroGen Pharma (URGN) CFO’s RSU grant?

The RSU grant to UroGen Pharma’s CFO shows a price per unit of $0.00. This is typical for equity awards granted as part of compensation, where units are awarded without a cash purchase but may be subject to service or performance-based vesting requirements.